At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A 24-week, Randomized, Double-blind, Multi-center, Parallel LCZ696 on NT-proBNP, Exercise Capacity, Symptoms and Safety Compared to Individualized Medical Management of Comorbidities in Patients With Heart Failure and Preserved Ejection Fraction
In Brief
A Phase 3 clinical trial evaluating sacubitril/valsartan, Enalapril, and 4 other interventions for Heart Failure With Preserved Ejection Fraction. Completed, enrolled 2,572 participants across 380 sites in 32 countries.
Detailed Summary
The purpose of this study is to demonstrate the superiority of LCZ696 over individualized medical therapy for comorbidities in reducing N-terminal pro-brain natriuretic peptide (NT-proBNP) and improving exercise capacity and HF symptoms in patients with heart failure with preserved ejection fraction (HFpEF).
Study Details
Timeline
Interventions
Sacubitril/valsartan is available as 24 mg/26 mg, 49 mg/51 mg, 97 mg/103 mg, respectively in tablet form to be taken orally
Enalapril is available as 2.5 mg, 5 mg, and 10 mg tablet form to be taken orally
Valsartan is available as 40 mg, 80 mg, 160 mg tablet form to be taken orally
Placebo to match LCZ696 50 mg, 100 mg, 200 mg tablet form to be taken orally
Placebo to match enalapril 2.5 mg, 5 mg, 10 mg tablet form to be taken orally
Placebo to match valsartan 40 mg, 80 mg, 160 mg tablet form to be taken orally